{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:06:57Z","timestamp":1778897217038,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":222,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"publisher","award":["C61984\/A2429"],"award-info":[{"award-number":["C61984\/A2429"]}],"id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100445","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T14:29:58Z","timestamp":1629210598000},"page":"100445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices"],"prefix":"10.1016","volume":"28","author":[{"given":"Catherine R.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen A.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Wincenciak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Iveson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100445_bib0001","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.2019.37.15_suppl.3501","article-title":"Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC)","volume":"37","author":"Iveson","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0002","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100445_bib0003","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2020.38.15_suppl.4004","volume":"38","author":"Sobrero","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0004","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.20.01330","article-title":"Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer","volume":"39","author":"Iveson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0006","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cjp2.171","article-title":"Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer","volume":"6","author":"Roseweir","year":"2020","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.ctarc.2021.100445_bib0007","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s41416-020-01168-x","article-title":"The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer","volume":"124","author":"Alexander","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2021.100445_bib0008","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","article-title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial","volume":"19","author":"Iveson","year":"2018","journal-title":"The Lancet. Oncology."},{"key":"10.1016\/j.ctarc.2021.100445_bib0009","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/annonc\/mdy064","article-title":"The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?","volume":"29","author":"Sobrero","year":"2018","journal-title":"Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2217\/crc-2017-0019","article-title":"How much is enough: 3 versus 6 months of adjuvant therapy for colon cancer","volume":"6","author":"Marshall","year":"2017","journal-title":"Colorectal Cancer"},{"key":"10.1016\/j.ctarc.2021.100445_bib0011","article-title":"Debate: 3 or 6 Months Adjuvant Therapy for Stage III Colon Cancer","volume":"40","author":"Fuerst","year":"2018","journal-title":"Oncology Times"},{"key":"10.1016\/j.ctarc.2021.100445_bib0012","doi-asserted-by":"crossref","first-page":"v210","DOI":"10.1093\/annonc\/mdz246.032","article-title":"Impact of the IDEA study on clinical practice for stage III colon cancer patients: a French GERCOR - FFCD - GI UNICANCER national survey","volume":"30","author":"Ouali","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0013","doi-asserted-by":"crossref","unstructured":"Yu I.S., Pereira A.A.L., Lee M., et\u00a0al. Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. The Oncologist. 2019.","DOI":"10.1634\/theoncologist.2019-0553"},{"key":"10.1016\/j.ctarc.2021.100445_bib0014","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2021.100445_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11864-015-0348-2","article-title":"Microsatellite instability testing and its role in the management of colorectal cancer","volume":"16","author":"Kawakami","year":"2015","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1741-7015-12-99","article-title":"Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes","volume":"12","author":"Glover","year":"2014","journal-title":"BMC Med."},{"key":"10.1016\/j.ctarc.2021.100445_bib0017","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41416-018-0319-z","article-title":"SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer","volume":"119","author":"Robles-Zurita","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2021.100445_bib0018","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","volume":"30","author":"Tournigand","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0019","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin As Adjuvant Therapy for Colon Cancer: updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0020","article-title":"Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: can a regional intervention promote national change?","author":"Taylor","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2021.100445_bib0021","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clon.2017.03.001","article-title":"Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: a Cancer Care Ontario Systematic Review","volume":"29","author":"Meyers","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0022","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdv003","article-title":"Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials","volume":"26","author":"Haller","year":"2015","journal-title":"Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0023","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2013.49.6638","article-title":"Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II\/III Colon Cancer: findings From the ACCENT Database","volume":"31","author":"McCleary","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0024","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.annonc.2019.12.007","article-title":"Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database","volume":"31","author":"Salem","year":"2020","journal-title":"Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0025","unstructured":"Excellence NIfHaC. Colorectal cancer NICE guideline [NG151] Published date: 29 January 2020 2020."},{"key":"10.1016\/j.ctarc.2021.100445_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab043","article-title":"The Early Impact of the IDEA Collaboration Results: how the Results Changed Prescribing Practice","author":"Iveson","year":"2021","journal-title":"JNCI Cancer Spectrum"},{"key":"10.1016\/j.ctarc.2021.100445_bib0027","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/annonc\/mdi116","article-title":"A randomised comparison between 6 months of bolus fluorouracil\/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer","volume":"16","author":"Chau","year":"2005","journal-title":"Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.ctarc.2021.100445_bib0028","unstructured":"Excellence NIfHaC. COVID-19 rapid guideline: delivery of systemic anticancer treatments 2020."},{"key":"10.1016\/j.ctarc.2021.100445_bib0029","unstructured":"Morris E.J.A., Goldacre R., Spata E., et\u00a0al. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. The Lancet Gastroenterology & Hepatology."},{"key":"10.1016\/j.ctarc.2021.100445_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.07.031","article-title":"A new prognostic and predictive tool for shared decision making in stage III colon cancer","volume":"138","author":"Sobrero","year":"2020","journal-title":"Eur. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:10:32Z","timestamp":1778893832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":30,"alternative-id":["S2468294221001428"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100445","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100445"}}